CA2514703A1 - Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma - Google Patents

Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma Download PDF

Info

Publication number
CA2514703A1
CA2514703A1 CA002514703A CA2514703A CA2514703A1 CA 2514703 A1 CA2514703 A1 CA 2514703A1 CA 002514703 A CA002514703 A CA 002514703A CA 2514703 A CA2514703 A CA 2514703A CA 2514703 A1 CA2514703 A1 CA 2514703A1
Authority
CA
Canada
Prior art keywords
hsgk1
hsgk3
gene
protein
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002514703A
Other languages
English (en)
French (fr)
Inventor
Florian Lang
Andreas Busjahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2514703A1 publication Critical patent/CA2514703A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • G01N2800/166Cataract
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • G01N2800/168Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002514703A 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma Abandoned CA2514703A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (de) 2003-02-07 2003-02-07 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
DE10305212.7 2003-02-07
PCT/EP2004/001048 WO2004069258A2 (de) 2003-02-07 2004-02-05 Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom

Publications (1)

Publication Number Publication Date
CA2514703A1 true CA2514703A1 (en) 2004-08-19

Family

ID=32730900

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002514703A Abandoned CA2514703A1 (en) 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma

Country Status (13)

Country Link
EP (1) EP1663246A2 (enExample)
JP (1) JP2006519189A (enExample)
KR (1) KR20050114214A (enExample)
CN (1) CN1771039A (enExample)
AU (1) AU2004210416A1 (enExample)
BR (1) BRPI0407300A (enExample)
CA (1) CA2514703A1 (enExample)
DE (1) DE10305212A1 (enExample)
MX (1) MXPA05008394A (enExample)
PL (1) PL378399A1 (enExample)
RU (1) RU2005127808A (enExample)
WO (1) WO2004069258A2 (enExample)
ZA (1) ZA200506280B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1964705A (zh) * 2004-03-11 2007-05-16 默克专利有限公司 干扰纤维化的方法
RU2006135654A (ru) * 2004-03-11 2008-09-10 Мерк Патент ГмбХ (DE) Способы модуляции глутаматных рецепторов для лечения нейропсихиатрических расстройств, включающие применение модуляторов сывороточных и индуцируемых глюкокортикоидами киназ
DE102004059781A1 (de) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
WO2007002670A2 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Method of lowering intraocular pressure
JPWO2007037560A1 (ja) * 2005-09-30 2009-04-16 リンク・ジェノミクス株式会社 Sgk2遺伝子の治療的又は診断的用途
JP5249774B2 (ja) * 2005-11-22 2013-07-31 マギル ユニバーシティ 眼内圧調節初期遺伝子およびその使用
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
BR112013018374A2 (pt) * 2011-01-25 2016-10-11 Monell Chemical Senses Centre composições e métodos para fornecer ou modular o sabor doce e métodos para rastrear os mesmos
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트
CN119303113A (zh) * 2024-09-03 2025-01-14 河北大学附属医院 Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006863A1 (en) * 1994-08-30 1996-03-07 University Of Dundee Agents for inducing apoptosis and applications of said agents in therapy
AU6263996A (en) * 1995-06-07 1996-12-30 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE19708173A1 (de) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Zellvolumenregulierte humane Kinase h-sgk
WO1999059559A1 (en) * 1998-05-15 1999-11-25 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
DE69937159T2 (de) * 1998-12-14 2008-06-26 University Of Dundee, Dundee Verfahren zur Aktivierung von SGK durch Phosphorylierung.
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
WO2001004145A2 (en) * 1999-07-14 2001-01-18 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US6416759B1 (en) * 1999-09-30 2002-07-09 The Regents Of The University Of California Antiproliferative Sgk reagents and methods
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets

Also Published As

Publication number Publication date
CN1771039A (zh) 2006-05-10
BRPI0407300A (pt) 2006-02-07
AU2004210416A1 (en) 2004-08-19
PL378399A1 (pl) 2006-04-03
RU2005127808A (ru) 2006-05-27
EP1663246A2 (de) 2006-06-07
JP2006519189A (ja) 2006-08-24
DE10305212A1 (de) 2004-08-19
WO2004069258A2 (de) 2004-08-19
KR20050114214A (ko) 2005-12-05
MXPA05008394A (es) 2005-10-05
WO2004069258A3 (de) 2005-02-24
ZA200506280B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
JP2007523197A (ja) pHSP20様活性を有する非ペプチジル剤、およびその使用
Gao et al. HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling
CA2514703A1 (en) Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma
Gan et al. FoxO-dependent and-independent mechanisms mediate SirT1 effects on IGFBP-1 gene expression
Trevaskis et al. Src homology 3-domain growth factor receptor-bound 2-like (endophilin) interacting protein 1, a novel neuronal protein that regulates energy balance
Bell et al. Induction of hypertrophic responsiveness of cardiomyocytes to neuropeptide Y in response to pressure overload
Bain et al. The mechanism for transcriptional activation of the human ATA2 transporter gene by amino acid deprivation is different than that for asparagine synthetase
CN100406570C (zh) 用作诊断和治疗靶标的Sgk和Nedd
CN1193756C (zh) 用作诊断和治疗靶点的sgk2和sgk3
Isshiki et al. Insulin regulates SOCS2 expression and the mitogenic effect of IGF-1 in mesangial cells
JP2019182873A (ja) 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法
EP0887081A2 (en) Human serum glucocorticoid regulated kinase, a target for chronic renal disease
Lee et al. The transcription factor Eya2 prevents pressure overload-induced adverse cardiac remodeling
EP1272517B1 (en) Multiprotein-complexes comprising a nmda receptor and uses thereof
Cho et al. Bovine type I collagen inhibits Raw264. 7 cell proliferation through phosphoinositide 3-kinase-and mitogen-activated protein kinase-dependent down-regulation of cyclins D1, A and B1
EP1698348A1 (en) Remedy/preventive for vascular disorders and hypertension and method of screening the same
EP1556505B1 (en) Modulation of s6 kinase activity for the treatment of obestiy
KR20050016494A (ko) 진단 및 치료 표적으로 사용되는 sgk 및 nedd
WO2008016118A1 (en) Agent targeting dopamine receptor and screening method therefor
JP4044842B2 (ja) 肥満を処置し得る薬剤のスクリーニング法
EP1837033A1 (en) REMEDY FOR DIABETES CONTAINING Cdk5 INHIBITOR
US20030068660A1 (en) Methods of ameliorating arthritis by modulating JNK signalsome activity
ICER Negative Regulation of TLR Responses by the
Zhang et al. AJP-Cell Articles in PresS. Published on May 29, 2002 as DOI 10.1152/ajpcell. 00048.2002
FALCENBERG LEHRSTUHL FÜR SYSTEMBIOLOGIE DER PFLANZEN

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued